Degarelix Acetate

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Adult
• State: Solid
• HS Code: 2937190090
• Production Capacity: 100000g/Month

Product Description

     Degarelix is a competitive and reversible gonadotropin-releasing hormone receptor (GnRHR/LHRHR) antagonist. Degarelix can be used for prostate cancer research.

Product Introduction
 

Generic name	Degarelix acetate
Synonyms	Firmagon, Degarelix acetate salt, N-Acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-    pyridyl)-D-alanyl-L-seryl-4-[2,6-dioxohexahydropyrimidin-4(S)-ylcarboxamido]-L-phenylalanyl-4-   ureido-D-phenylalanyl-L-leucyl-N6-isopropyl-L-lysyl-L-prolyl-D-alaninamide acetate, D-laninamide,   N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-4-   [[[(4S)-hexahydro-2,6-dioxo-4-pyrimidinyl]carbonyl]amino]-L-phenylalanyl-4-[(aminocarbonyl)amino]-   D-phenylalanyl-L-leucyl-N6-(1-methylethyl)-L-ly
Formula	C82H103ClN18O16
CAS No.	214766-78-6
Molecular Weight	1632.26
EINECS	807-277-4

  Chemical Properties

Density	1.325±0.06 g/cm3(Predicted)
Storage Condition	Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
pka	10.38±0.40(Predicted)

Application & Efficacy

       Degarelix acetate is a gonadotropin-releasing hormone receptor blocker, which has been approved in the United States and Europe respectively For the treatment of advanced (hormone-dependent) prostate cancer, it is approved for the treatment of prostate cancer in Japan.